Leerink Partners analyst Mike Kratky has maintained their neutral stance on EW stock, giving a Hold rating yesterday.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Mike Kratky has given his Hold rating due to a combination of factors concerning Edwards Lifesciences. A primary reason is the uncertainty surrounding the JenaValve deal, which has been delayed and now carries a heightened risk of not closing. This uncertainty poses a potential threat to future growth opportunities, as the JenaValve’s Trilogy system could have added a valuable self-expanding valve option to Edwards’s offerings.
Furthermore, although the company has adjusted its 2025 earnings per share guidance upwards to reflect the removal of expected dilution from the deal, there is no anticipated impact on revenue guidance for 2025. The management’s proactive measures to adjust EPS guidance indicate a cautious approach, yet the potential loss of the JenaValve deal remains a concern for long-term growth prospects. These factors collectively contribute to the Hold rating, as the potential benefits are counterbalanced by the risks involved.
In another report released yesterday, Robert W. Baird also maintained a Hold rating on the stock with a $81.00 price target.
EW’s price has also changed moderately for the past six months – from $70.990 to $78.610, which is a 10.73% increase.